Drugs / CD30 biAb-AATC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05544968 | Mar 2026 → Jan 2028 expected | Hodgkins lymphoma, anaplastic large cell lymphoma, diffuse large B-cell lymphoma, large-cell immunoblastic lymphoma +2 | Medical College of Wisconsin | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD30 biAb-AATC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05544968 ↗ |
| Modality | Cell therapy | “preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells” NCT05544968 ↗ |